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1. Introduction
Obesity, with its constellation of related metabolic diseases,
such as type 2 diabetes (T2D), has become a major public health
problem worldwide in view of its associated morbidity and
mortality, and the increasingly large number of individuals
affected. Greater consumption of energy-dense foods and an
overall shift towards more sedentary lifestyles are important
factors contributing to this unprecedented rise in prevalence [1],
with genetic predisposition apparently playing a relatively minor
role [2,3]. More recently, the gutmicrobiome has elicited a surge of
interest as a possible contributor to the pathogenesis of obesity
and T2D. Obesity appears to be associated with reduced bacterial
diversity and changes in the relative abundance of different
bacterial species [3,4]. Studies have indicated differences in gut
microbiota between obese and lean individuals [2], as well as
between diabetic and non-diabetic individuals [5,6]. Experiments
in various animal models have consistently demonstrated that the
gut microbiota affects host metabolism in numerous ways. In
particular, it can modify the amount of energy harvested from the
diet, the integrity of the intestinal barrier, the qualitative
composition and metabolism of fatty acids in adipose tissue and
the liver, the secretion of gut-derived peptides, and lipopolysac-








A multispecies Lactobacillus- and Bifidobacterium-containing probiotic mixture significantly reduced the adverse metabolic and 
inflammatory effects of a 14-week high-fat diet in wild-type C57/BL6J mice gavaged 5 days a week with the probiotic mixture or 
vehicle. Recent evidence indicates that the gut microbiome may play a decisive role in the onset of obesity and associated chronic 
metabolic diseases, such as type 2 diabetes, by modulating nutrient absorption and factors conducive to development of a persistent 
low-grade inflammatory state. By modifying the gut microbiome, probiotics might constitute an effective dietary strategy for 
managing these metabolic disorders. The tested probiotic mixture significantly attenuated the increase in body weight, serum 
glucose concentration and insulin resistance induced by the high-fat diet. Furthermore, it significantly reduced the up-regulation of 
expression of several genes encoding pro-inflammatory adipokines and leukotriene pathway enzymes (CCL-2, IL-6 and leukotriene 
C4 synthase in adipose tissue, leukotriene C4 synthase and leukotriene A4 hydrolase in the gut). It also significantly counteracted the 
down-regulation of adipose tissue gene expression related to the anti-inflammatory adipokine adiponectin in mice fed the high-fat 
diet. These results suggest that the mechanism underlying the beneficial metabolic effects of the probiotic mixture might involve 
inhibition of gut and adipose tissue inflammation.
Abbreviations: CLAs, conjugated linoleic acids; CT, control diet; FIAF, fasting-
induced adipocyte factor; GLP-1, glucagon-like peptide-1; HF, high-fat diet; HF-Pb,
high-fat diet with probiotic mixture; 5-HPETE, 5-hydroperoxyeicosatetraenoic
acid; IBS, inflammatory bowel syndrome; LPS, lipopolysaccharide; LTA4H,
leukotriene A4 hydrolase; LTC4S, leukotriene C4 synthase; Pb, probiotic mixture;
SREBP-1, sterol regulatory element-binding protein 1; T2D, type 2 diabetes; Treg
cells, T regulatory cells.
* Corresponding author. Tel.: +33 1 53 86 70 72; fax: +33 1 56 58 01 44.
E-mail address: s.holowacz@larenasante.com (S. Holowacz).
http://dx.doi.org/10.1016/j.phanu.2015.03.003 ß 
Metabolic disorders, including obesity and T2D, are associated
witha state of chronic, low-grade inflammation inperipheral tissues
and the circulation [8]. Expansion of adipose tissue is accompanied
by enhanced secretion of pro-inflammatory adipokines, e.g. IL-6 and
CCL-2, and reduced secretion of the anti-inflammatory and insulin-
sensitizing adipokine, adiponectin [9]. This results in chronic, low-
grade inflammation affectingmultiple tissues and organs, including
the liver, skeletal muscle and heart [10]. Adipose and peripheral
inflammation may favour the development of debilitating beha-
vioural symptoms, including depressive symptoms and cognitive
impairment [11], as well as various chronically painful conditions,
suchasosteoarthritis [12]. Spinal adiponectinmRNAexpressionwas
found to bemodified in obese rats, suggesting that adiponectinmay
also promote centrally mediated pathological changes underlying
obesity-related exacerbation of pain and inflammation [13].
A logical corollary of these observations is that manipulation of
the gut microbiota by qualitative and quantitative changes in the
intake of specific food components, such as fatty acids [14], high-
protein diets [15], probiotics [16,17] and prebiotics [18,19] could
be an effective dietary strategy to manage lifestyle-related
metabolic disorders such as obesity and T2D. Besides decreasing
abdominal adiposity and total cholesterol, probiotics can normal-
ize low-grade inflammation and favour mucosal integrity [20].
Recent studies have indicated that certain bacterial strains may
prevent diet-induced obesity and related disorders. Lactobacillus
rhamnosus PL60 and L. plantarum PL62, bacterial species capable of
producing conjugated linoleic acids (CLAs) conducive to body fat
reduction, have been shown to exert beneficial effects on diet-
induced obesity inmice. Consumption of fermented skimmedmilk
containing Lactobacillus gasseri SBT2055 regulated adipose tissue
growth in rats, possibly through inhibition of dietary fat
absorption. Lactobacillus curvatus HY7601 and L. plantarum
KY1032 reduced weight gain and fat accumulation in diet-induced
obesity in mice by modulating pro-inflammatory genes in adipose
tissue and fatty acid oxidation-related genes in the liver [16].
In the study presented here, we investigatedwhether treatment
with a multispecies probiotic mixture comprising five bacterial
strains (Lactobacillus acidophilus, L. plantarum, L. salivarius and two
strains of Bifidobacterium lactis) could attenuate experimental
obesity induced in mice by a high-fat diet. Previous studies
conducted by our group demonstrated the anti-inflammatory
properties of this probiotic mixture [21] and also showed that it
can prevent disruption of the gut epithelial barrier and up-regulate
the expression of tight-junction proteins [22]. Our objective was to
further explore the metabolic effects of the probiotic mixture and
the potentialmechanisms underlying its anti-inflammatory action.
2. Materials and methods
2.1. Probiotic mixture
The tested probiotic dietary supplement (Lactibiane Tole´r-
ance1, PiLeJe, France) comprises a mixture of five viable
lyophilized lactic acid bacterial strains (B. lactis LA 303, B. lactis
LA 304, L. acidophilus LA 201, L. plantarum LA 301 and L. salivarius
LA 302) at a total concentration of 1  1010 colony-forming units
(CFU) per capsule. Fresh suspensions of the lyophilized probiotic
mixture (Pb) were prepared daily in sterilized phosphate-buffered
saline (PBS) and administered intragastrically to mice at the dose
of 1  109 CFU/mouse (in 0.2 mL of PBS) on 5 consecutive days a
week for 14 weeks.
2.2. Animals and experimental diets
The study was performed according to French government
guidelines for animal experiments (protocol number 12/1048/03/
15). Twenty-seven male C57/BL6J mice aged 6 weeks at the
beginning of the experiment (Charles River Laboratories, France)
were housed in groups of three per cage in a controlled
environment (12-h daylight cycle) with free access to food and
water. After twoweeks of acclimatization, themicewere randomly
allocated to receive for 14 weeks one of three different
experimental diets (n = 9/group): (1) a control (CT) diet (A04,
SAFE, Villemoison-sur-Orge, France) containing (w/w) 16.1%
protein, 60% carbohydrate and 3.1% fat (total energy supply:
2.9 kcal/g consumed); (2) a high-fat (HF) diet (Research Diet Inc.)
containing 26% protein, 26% carbohydrates and 35% trans-type
saturated fats (total energy supply: 5.2 kcal/g consumed); (3) the
HF diet plus the probiotic mixture (1  109 CFU/mouse adminis-
tered in 0.2 mL sterilized PBS by oral gavage on 5 consecutive days
per week) (HF-Pb diet). The groups allocated to the CT and HF diets
received the same volume of sterilized PBS alone by oral gavage on
5 consecutive days a week during 14 weeks.
At the end of the experiment, the mice were killed by cervical
dislocation. The small intestine (from duodenum to ileum), colon,
and subcutaneous and perigonadal adipose tissues were excised,
rinsed with physiological saline solution, weighed and stored at
ÿ70 8C pending further analysis.
2.3. Body weight and fat mass measurement
Body weights were recorded in all three groups of mice once a
week. Body fat percentage was measured at week 13 by nuclear
magnetic resonance (NMR) using an EchoNMRTM 100H apparatus
(Echo Medical Systems LLC, New York, USA). Mice were placed in a
clear plastic holder for scanning, without sedation. Fat and lean
masses were determined on the basis of the differences in
relaxation times of the hydrogen proton spins in disparate
environments. Fat mass corresponds to the mass of all fat
molecules in the body and is expressed as the equivalent weight
of canola oil. Lean (muscle tissue) mass corresponds to all water-
containing body parts excluding fat, boneminerals, hair, claws, etc.
At the end of the study (week 14), perigonadal and subcutaneous
adipose tissues were excised and weighed separately.
2.4. Determination of blood glucose, insulin and homeostasis index
(HOMA-IR)
Blood samples (5mL)were taken from the tail, after a 6-h fast, at
baseline (before allocation to the experimental diets) and at weeks
6 and 12. Serum glucose and insulin concentrations were
determined using a glucometer and by ELISA, respectively. The
glucometric assay was chosen for measurement of serum glucose
concentrations as it requires small blood volumes, reducing stress
on the animals. Insulin resistance was determined as HOMA-IR,
calculated according to the equation HOMA-IR = fasting serum
glucose concentration (mg/mL)  fasting serum insulin concen-
tration (mIU/mL)/22.5.
2.5. Expression of genes encoding pro- or anti-inflammatory agents in
adipose (perigonadal or subcutaneous) and gut (small intestine or
colon) tissues
Tissues were disrupted using a tissue homogenizer (Precellys1,
Ozyme, France) in the presence of lysis buffer (QIAzol1, Qiagen,
France; 1 mL per 100 mg of tissue). Total mRNA was isolated from
adipose tissues and gut using a solid-phase RNA purification kit
(GenJET1, Fermentas, France) and by classical liquid/liquid (phenol/
chloroform) extraction, respectively. Reverse transcriptionwas then
performed on 1mg samples of mRNA from each tissue using a
SupersScript II kit (Invitrogen, France), according to themanufac-
turer’s protocol. Samples were prepared for high-throughput
real-time qPCR on a BioMark 96.96 Dynamic Array (Fluidigm,
France) according to themanufacturer’s protocol. Real-time qPCR
was chosen for this analysis as being the most appropriate means
of assessing several genes in a single real-time experiment.
2.6. Statistical evaluation
Data are expressed as means  standard deviation (SD). CT, HF
and HF-Pb treatment groups were compared using one-way ANOVA
for multiple comparisons with Tukey’s post hoc test. Repeated
measures ANOVAwas used to determine the statistical significance of
intergroup differences in body weight at successive time points. The
95% confidence interval was calculated and statistical significance
was concluded at p < 0.05.
3. Results
3.1. Anti-obesity effect of the probiotic mixture
As expected, body weight increased to a greater extent in mice
fed the high-fat diet than in those consuming the control diet, the
difference between these two groups being significant from 6
weeks onwards. However, the bodyweight increase induced by the
high-fat diet was reduced by concomitant administration of the
probioticmixture, the difference between theHF andHF-Pb groups
being statistically significant from week 10 to the end of the study
at week 14 (Fig. 1). Themean bodyweight gains during the total 14
weeks of experimental diet consumption were 6.23  1.67 g,
18.71  1.53 g and 15.20  0.65 g in the CT, HF and HF-Pb groups,
respectively, the difference between the HF and HF-Pb groups being
statistically significant. Themean total weight gain determined at the
end of the study (week 14) was 41.9  3.1% higher in the HF group
and 28.3  4.4% higher in the HF-Pb group than in the CT group. The
HF-Pb group showed a lower proportion of fat mass (30.7 versus
36.1%) and a higher proportion of lean mass (54.4 versus 49.1%),
compared to the HF group (Fig. 2, panels A and B), but the differences
between the two groups were not significant (p > 0.05). Perigonadal
and subcutaneous adipose tissue weights were significantly de-
creased, by 22.1% and 21.2% respectively, in HF-Pb mice compared to
HF mice (Fig. 2, panels C and D).
3.2. Serological analyses
Mean serum glucose and insulin concentrations determined at
week 12were significantly higher in the HF and HF-Pb groups than
in the CT group, but significantly lower (by 17 and 37%,
respectively) in the HF-Pb group compared to the HF group
(Table 1). Similarly, mean HOMA-IR, a representative index of
insulin resistance, was significantly higher in both the HF and HF-
Pb groups than in the CT group, but significantly reduced by 47% in
the HF-Pb group compared to the HF group (Table 1).
3.3. Expression of genes encoding pro- or anti-inflammatory agents in
adipose and gut tissues (high-throughput real-time qPCR analysis)
3.3.1. Effect of the probiotic mixture on adipokine gene expression in
adipose tissue
Compared to the CT group, the HF group showed 12.6-fold and
7.2-fold higher expression levels of the gene encoding the pro-
inflammatory adipokine CCL-2 in the perigonadal and subcutane-
ous adipose tissue, respectively (Fig. 3). These elevations in CCL-2
gene expression induced by the high-fat diet were significantly
reduced (2.6- and 1.7-fold, respectively) by concomitant intake of
the probiotic mixture (Fig. 3). In contrast, CCL-2 gene expression in
the small intestine and colon did not differ significantly between
the HF and HF-Pb groups. The elevation of IL-6 gene expression
induced by the HF diet in the perigonadal adipose tissue was
significantly (1.6-fold) reduced by concomitant intake of the
probiotic mixture. Expression of the gene encoding the anti-
inflammatory adipokine, adiponectin, in this tissue was signifi-
cantly (1.8-fold) increased in the HF-Pb group compared to the HF
group, approaching the level observed in the control group (Fig. 4).
In the perigonadal adipose tissue, no significant differences were
observed between the CT and HF-Pb groups with regard to CCL-2,
IL-6 and adiponectin gene expression.
3.3.2. Effect of the probiotic mixture on the expression of genes
encoding enzymes of the leukotriene pathway
The mRNA expression of leukotriene A4 hydrolase (LTA4H),
implicated in the production of LTB4, and that of leukotriene C4
synthase (LTC4S), an enzyme involved in the synthesis of the
cysteinyl leukotrienes C, D and E, were also evaluated (Fig. 5,
panels A and B respectively). Statistically significant inhibition
of LTA4H gene expression in adipose and colon tissues was
observed in the HF-Pb group compared to the HF group. LTC4S
gene expression was also significantly inhibited in the HF-Pb
group compared to the HF group with regard to gut (small
intestine and colon) tissues. The level of LTC4S gene expression
in the perigonadal and subcutaneous adipose tissues did not
differ significantly between the HF and HF-Pb groups. Adminis-
tration of the probioticmixture in conjunctionwith the high-fat
diet also led to significantly (1.5-fold) up-regulated expression
of the gene encoding the LXA4 receptor Fpr2 in the colon,
compared to that observed in mice receiving the high-fat diet
alone (Table 2).
3.3.3. Effect of the probiotic mixture on T regulatory gene expression
The mRNA expression of three T regulatory genes encoding
agentsmodulating inflammation, namely Foxp3, CD25 and IL-10 in
colon tissue was up-regulated in the group consuming the high-fat
diet compared to their expression in the control group. Concomi-
tant administration of the probioticmixture significantly increased
the expression of these T regulatory genes in colon tissue by 1.5–
2.3-fold compared to the HF group (Table 2). A trend towards
enhanced (1.6-fold) expression of CD25 in perigonadal adipose
tissue and small intestine tissue was observed in the HF-Pb group
compared to the HF group.
4. Discussion
The role of the gut microbiota in the pathogenesis of obesity-
related disorders is increasingly recognized and may involve the
provision of additional energy by the conversion of dietary fibres to
[(Fig._1)TD$FIG]
Fig. 1.High-fat diet and probiotic effect on bodyweight (g). Themice fed the control
diet (CT) (^), the high-fat diet (HF) (~), and the high-fat diet plus the probiotic
mixture (HF-Pb) (4) were weighed once a week and the results averaged. Data are
presented as the mean  SD. a p < 0.05 HF versus CT; b p < 0.05 HF-Pb versus HF.
short-chain fatty acids, effects on gut-hormone production, and
increased intestinal permeability leading to elevated systemic
lipopolysaccharide (LPS) levels [23]. The ability of probiotics and
prebiotics to reduce intestinal permeability has been tested in
various animal models of metabolic disorders [24]. The aim of our
study was to investigate the effects of concomitant administration
of a probiotic mixture to mice fed a high-fat diet on body weight,
glucose metabolism and the expression of genes encoding agents
modulating inflammatory processes, as obesity is known to be
associated with a state of chronic low-grade inflammation [8].
Previous studies have demonstrated the anti-inflammatory
properties of the tested probiotic mixture [21] as well as its
capacity to restore epithelial barrier disruptions induced by LPS,
stress or soluble factors associated with irritable bowel syndrome
(IBS) and to down-regulate the response mediated by the
inflammatory cytokine TLR-4 in vitro and in vivo [22]. In this
study, administration of this probiotic mixture for 14 weeks to
mice fed a high-fat diet diminished the increase in body weight
gain and body fat mass observed in mice receiving the same high-
fat diet alone. It also protected mice from the insulin resistance
induced by the high-fat diet as shown by the HOMA-IR values
determined in the HF and HF-Pb groups.
The chemokine CCL-2, produced by adipocytes, has a pivotal
role in the recruitment of macrophages into the peripheral adipose
tissue and contributes to the insulin resistance and hepatic
[(Fig._2)TD$FIG]
Fig. 2.High-fat diet and probiotic effects on fat mass (A), leanmass (B), perigonadal adipose tissue (C) and subcutaneous adipose tissue (D) weights. a p < 0.05 HF versus CT; b
p < 0.05 HF-Pb versus HF; cp < 0.05 HF-Pb versus CT.
Table 1
Serum glucose and insulin concentrations and HOMA-IR determined 12weeks after







Glucose (mg/dl) 1247 1766a 1468b
Insulin (pmol/mL) 48415 1315167a 83594b
HOMA-IR 1.2090.076 4.7050.747a 2.4830.359b
Data are presented as the mean SD.
a p<0.05 versus the CT group.
b p<0.05 versus the HF group.
[(Fig._3)TD$FIG]
Fig. 3. Relative expression of CCL-2 mRNA in adipose and gut tissues mice fed a
control diet (&), a high-fat diet alone ( [TD$INLINE] ) or a high-fat diet plus the probiotic
mixture (&). a p < 0.05 HF versus CT; b p < 0.05 HF-Pb versus HF; c p < 0.05 HF-Pb
versus CT.
steatosis associated with obesity. Previous studies have shown
enhanced expression of the CCL-2 gene in genetically obese
diabetic (db/db) mice and in wild type mice with obesity induced
by a high-fat diet [25], in obesemice compared to normalmice [26]
and in adipose tissues of obese patients compared to lean controls
[27]. In our study, the increase in CCL-2 mRNA expression in
perigonadal and subcutaneous adipose tissue observed in mice
consuming the high-fat diet compared to the control diet was
significantly reduced by intake of the probiotic mixture. Concomi-
tant administration of the probiotic mixture also significantly
inhibited the up-regulation of IL-6 and down-regulation of
adiponectin in perigonadal adipose tissue observed in mice fed
a high-fat diet.
Inflammation of the intestine, which is closely connected to the
visceral adipose tissue via blood vessels has also been observed in
the early phase of developing obesity [28]. In this study, the
expression of genes implicated in inflammatory processes in the
gut was explored using microfluidic tools. Real-time PCR analysis
revealed a significant impact of the tested probiotic mixture on the
expression of genes encoding enzymes of the leukotriene pathway
and Treg genes in colon tissue from mice fed a high-fat diet,
demonstrating its effect on inflammatory processes. The leukotri-
ene precursor arachidonic acid 5-hydroperoxide (5-hydoperox-
yeicosatetraenoic acid; 5-HPETE) may be converted into either
LTB4, via the activation of LTA4H, or into LXA4, via inhibition of this
enzyme, LTC4, LTD4 and/or LTE4 being produced via activation of
LTC4S. Our study showed a decrease in LTA4H and LTC4S mRNA
expression in mice receiving the probiotic mixture in addition to
the high-fat diet. This suggests that inhibition of both enzymes
might lead to enhanced LXA4 production in gut tissue. The
hypothesis that probiotics affect the expression of genes involved
in immunosuppression and resolution of inflammation is sup-
ported by the increase in expression of Fpr2 (LXA4 receptor) mRNA
observed inmice receiving the tested probiotic mixture in addition
to the high-fat diet.
Chen et al. recently investigated the effects of LTB4 on the
differentiation of immunosuppressive CD4+CD25+Foxp3+Treg cells
in vitro and found that LTB4 dose-dependently decreased the
percentage of Treg cells and the mRNA expression of Foxp3 [29].
Foxp3+Treg cells, defined by expression of the forkhead family
transcription factor p3 (Foxp3) and high levels of the IL-2 receptor-
a chain (CD25), constitute a subset of CD4+Treg cells with the
function of suppressing immune responses and maintaining self-
tolerance [30]. The proportion of circulating CD25+CD127ÿFoxp3+-
+Treg cells in the total CD4+ cell population is inversely correlated
with indices of adiposity such as bodyweight, bodymass index and
circulating leptin levels, particularly in obese subjects. Moreover,
significantly fewer Treg cells are seen in individuals exhibiting
elevated markers of systemic inflammation (hsCRP) or impaired
glucose tolerance (HbA1c) [31]. A link between the leukotriene
pathway enzymes and Treg cells was observed by Bo¨rgeson et al.
[32] who showed that LXA4 increased expression of the anti-
inflammatory cytokine IL-10 in adipose tissue explants from
perigonadal fat depots of mice. In our study, we demonstrated that
probiotic supplementation not only modified the expression of
genes encoding enzymes implicated in the leukotriene pathway in
mice fed a high-fat diet but also significantly increased Foxp3,
CD25, and IL-10 mRNA expression in colon tissue.
In conclusion, probiotic supplementation significantly attenu-
ated body weight gain and protected mice from glucose intoler-
ance and insulin resistance induced by a high-fat diet. Gene
expression analysis indicated that these effects are at least in part
[(Fig._4)TD$FIG]
Fig. 4. Relative expression of IL-6 and adiponectin mRNA in perigonadal adipose
tissue of mice fed a control diet (&), a high-fat diet alone ( [TD$INLINE] ) or a high-fat diet plus
the probiotic mixture (&). a p < 0.05 HF versus CT; b p < 0.05 HF-Pb versus HF.
[(Fig._5)TD$FIG]
Fig. 5. Relative expression of LTA4H (A) and LTC4S (B) mRNA in adipose and gut
tissues of male C57/BL6J mice fed a control diet (&), a high-fat diet alone ([TD$INLINE] ) or a
high-fat diet plus the probiotic mixture (&). a p < 0.05 HF versus CT; b p < 0.05 HF-
Pb versus HF; c p < 0.05 HF-Pb versus CT.
Table 2








Fpr2 1.00 0.09 2.010.27a 2.980.29b
Foxp3 1.00 0.19 2.880.36a 4.460.60b
CD25 1.00 0.05 1.860.20a 2.970.28b
IL-10 1.00 0.12 1.160.12 2.640.44b,c
Data are presented as the mean SD.
a p<0.05 versus the CT group.
b p<0.05 versus the HF group.
c p<0.05 versus the CT group.
due to the anti-inflammatory actions of this probiotic mixture. In
adipose tissue, probiotic treatment reduced expression of the gene
encoding CCL-2, an important chemokine for macrophage infiltra-
tion of adipose tissue. In colon tissue, this treatment increased the
expression of genes involved in the immunosuppression and
resolution of inflammation. However, full-scale clinical trials
would be required to assess the value of the tested probiotic with
regard to the development of obesity and associated inflammatory
processes in humans. Further studies would also be needed to
elucidate the exact mechanisms underlying the effects of the
tested probiotic mixture with regard to its anti-inflammatory
impact on the gut immune system, its modification of gut
microbiota, its ability to reduce overall energy intake and its
modulation of gut hormone expression. The gut microbiota may
participate in the regulation of energy metabolism, i.e. the energy
harvested from the diet, as well as the regulation of fat storage
(expression of FIAF), fat lipogenesis (aceyl-CoA carboxylase, fatty
acid synthase, SREBP-1), and fatty acid oxidation (AMPK activity)
[33]. Modulation of gut peptides involved in appetite regulation,
such as GLP-1 and PYY, could be another mechanism by which the
gut microbiota might control energy and glucose homeostasis.
Data obtained in experimental models and in clinical studies have
already shown that changing the gut microbiota by means of
prebiotics (such as fructans) [18,34] or probiotics (such as
Lactobacillus casei W8) [35] may contribute to regulating gut
peptide synthesis and controlling food intake. So it might be
interesting to complete this study by investigating whether the
beneficial effect of our probiotic mixture on body weight gain
could be explained by reduced food intake and/or increased energy
expenditure, and to investigate more precisely the underlying
mechanisms of action.
Layperson’s summary
The nature of the microorganism population in the gut was
recently identified as a potential contributor to the increased
prevalence of obesity and type 2 diabetes. In this study, we
investigated the effects of a probioticmixture inmice fed a high-fat
diet conducive to the development of obesity. The weight gain and
increases in blood glucose level and insulin resistance induced by
this diet were significantly reduced by probiotic supplementation.
Improvement in the inflammatory state of the gut and adipose
tissue might be a possible mechanism underlying the anti-obesity
effect of the probiotic mix studied.
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